Arch continues non-viral gene therapy interest with SonoThera launch

In less than three months, Arch Venture Partners has backed its second non-viral gene therapy company with the launch of SonoThera Inc. 

The San Francisco-based biotech announced Monday that it raised $60.8 million in a series A round led by Arch. SonoThera is developing a gene therapy delivery platform that uses sonoporation, a technique that encapsulates genetic material within microbubbles to non-invasively deliver genetic payloads of diverse formats and sizes to a wide range of selectively targeted organs within the body...